PH12017501157B1 - Mixture of carboxylic acids for treating patients with kidney failure - Google Patents

Mixture of carboxylic acids for treating patients with kidney failure

Info

Publication number
PH12017501157B1
PH12017501157B1 PH12017501157A PH12017501157A PH12017501157B1 PH 12017501157 B1 PH12017501157 B1 PH 12017501157B1 PH 12017501157 A PH12017501157 A PH 12017501157A PH 12017501157 A PH12017501157 A PH 12017501157A PH 12017501157 B1 PH12017501157 B1 PH 12017501157B1
Authority
PH
Philippines
Prior art keywords
treatment
patients
acid
replacement therapy
kidney
Prior art date
Application number
PH12017501157A
Other versions
PH12017501157A1 (en
Inventor
Miramontes Jorge Antonio Hernandez
Villanueva Jorge Alberto Hernandez
Original Assignee
Miramontes Jorge Antonio Hernandez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56234463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12017501157(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Miramontes Jorge Antonio Hernandez filed Critical Miramontes Jorge Antonio Hernandez
Publication of PH12017501157B1 publication Critical patent/PH12017501157B1/en
Publication of PH12017501157A1 publication Critical patent/PH12017501157A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/20—Sebacic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Currently the treatment for patients with terminal kidney disease (stage V) consists in renal replacement therapy (hemodialysis, peritoneal dialysis or kidney transplant) which is extraordinarily expensive and engenders poor quality of life. The present invention is a mixture of carboxylic acids: citric acid, succinic acid, fumaric acid and malic acid, and any of the possible combinations thereof. Said product is preferably administered orally or intravenously, in the treatment of patients with chronic kidney disease, hyperammonemia or human conditions involving a negative nitrogen balance. This product is useful for reducing the serum values of urea and serum ammonium, while at the same time, by transamination of the oxaloacetate formed via succinate, fumarate and malate, it promotes the biosynthesis of non-essential, amino acids, and by transamination of the alpha-ketoglutarate formed via citrate, it generates glutamic acid and the amino acids related to same such as glutamine. This treatment prevents, preserves and even improves kidney function. In other patients it delays the deterioration of the kidney failure and the urgent need for renal replacement therapy. In others, it is used as a treatment that complements the renal replacement therapy in order to improve the quality of life of the patient and to improve the laboratory parameters.
PH12017501157A 2015-03-20 2017-06-20 Mixture of carboxylic acids for treating patients with kidney failure PH12017501157A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2015003641A MX357998B (en) 2015-03-20 2015-03-20 A mixture of carboxylic acids, more specifically, citric acid, succinic acid, fumaric acid, malic acid, and their use for the treatment of patients with chronic renal failure, acute renal failure, acute or chronic hepatopathies associated with hyperamonemia, congenital diseases with enzymatic alterations in the urea cycle, as well as clinical conditions associated with a negative nitrogen balance.
PCT/MX2015/000144 WO2016153331A1 (en) 2015-03-20 2015-11-04 Mixture of carboxylic acids for treating patients with kidney failure

Publications (2)

Publication Number Publication Date
PH12017501157B1 true PH12017501157B1 (en) 2017-11-27
PH12017501157A1 PH12017501157A1 (en) 2017-11-27

Family

ID=56234463

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12017501157A PH12017501157A1 (en) 2015-03-20 2017-06-20 Mixture of carboxylic acids for treating patients with kidney failure

Country Status (26)

Country Link
US (2) US10688068B2 (en)
EP (1) EP3219315B1 (en)
JP (1) JP6771191B2 (en)
KR (1) KR102057555B1 (en)
CN (1) CN108024981B (en)
AU (1) AU2015387986B2 (en)
BR (1) BR112017017189A2 (en)
CA (1) CA2972889C (en)
CL (1) CL2017001262A1 (en)
CO (1) CO2017007046A2 (en)
CR (1) CR20170320A (en)
DO (1) DOP2017000161A (en)
EA (1) EA036702B1 (en)
EC (1) ECSP17056559A (en)
ES (1) ES2850998T3 (en)
GT (1) GT201700149A (en)
HK (1) HK1249426A1 (en)
IL (1) IL253480B (en)
MX (1) MX357998B (en)
MY (1) MY173111A (en)
NZ (1) NZ733186A (en)
PE (1) PE20180228A1 (en)
PH (1) PH12017501157A1 (en)
SG (1) SG11201705163XA (en)
TN (1) TN2017000257A1 (en)
WO (1) WO2016153331A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7219898B2 (en) * 2017-04-18 2023-02-09 国立大学法人東北大学 Blood purification with alkaline agents
WO2018193648A1 (en) * 2017-04-18 2018-10-25 国立大学法人東北大学 Blood purification through alkalifying agent
IT201700087359A1 (en) 2017-07-28 2019-01-28 Professional Dietetics Spa COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
IT201700087376A1 (en) 2017-07-28 2019-01-28 Professional Dietetics Spa COMPOSITIONS INCLUDING AMINO ACIDS FOR USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH MITOCHONDRIAL DYSFUNCTION
WO2020080499A1 (en) * 2018-10-17 2020-04-23 国立大学法人東北大学 Novel pharmaceutical composition
CN109125310A (en) * 2018-11-06 2019-01-04 河北工业大学 Succinic acid is inhibiting application and drug in Kv10.1 ion channel activity
EP3976559A4 (en) 2019-05-30 2023-06-21 Koch Agronomic Services, LLC Micronutrient foliar solutions
US11666548B2 (en) * 2020-06-05 2023-06-06 Baxter International Inc. Parenteral nutrition formulation
CN115414383A (en) * 2022-10-14 2022-12-02 青岛普瑞森医药科技有限公司 Hemodialysis concentrated solution and preparation method thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475031A (en) * 1993-09-03 1995-12-12 Livingston; William H. Discovery of a valuable property for succinic acid and other intermediary metabolites
US5500232A (en) * 1994-10-06 1996-03-19 Bristol-Myers Squibb Company Calcium fortified beverages
US6488961B1 (en) * 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
EP0938849A1 (en) 1998-02-18 1999-09-01 Quest International B.V. A composition with a fresh, fruit like taste
US6288116B1 (en) * 1998-05-13 2001-09-11 Novartis Nutrition Ag Method of administration of a nutritional product to a person having renal failure
AU7032700A (en) * 1999-10-12 2001-04-23 Meiji Seika Kaisha Ltd. Low potassium juice, method for producing thereof and food containing the same
ATE375095T1 (en) * 2000-10-16 2007-10-15 Pepsico Inc METHOD FOR PRODUCING CALCIUM ENRICHED BEVERAGES
US20030211204A1 (en) * 2002-05-10 2003-11-13 Fields Christine C. Method of preparing beverages and beverage concentrates nutritionally supplemented with minerals
US20090186127A1 (en) * 2004-12-15 2009-07-23 Krumhar Kim C Energy drink compositions
BRPI0602825A2 (en) * 2006-06-23 2012-04-24 Rhodia Br Ltda self-cooling effervescent powder formulation for beverages and use of effervescent powder formulation
US20080058421A1 (en) 2006-09-05 2008-03-06 John Alex Lopes Compositions for cleaning and disinfecting nasal tract and sinus cavity
TWI440457B (en) * 2006-12-12 2014-06-11 Ajinomoto Kk Use of citric acid and/or a citrate salt containing composition
CN101568334A (en) * 2006-12-12 2009-10-28 味之素株式会社 Iron metabolism-improving agent
US20080226799A1 (en) * 2007-03-14 2008-09-18 Concentrate Manufacturing Company Of Ireland Diet Cola Beverages
US8129430B2 (en) * 2007-08-31 2012-03-06 C.B. Fleet Company, Inc. Method of reducing phosphate nephropathy in a mammal
JP5740393B2 (en) 2009-05-15 2015-06-24 バイオセプタ コーポレイションｂｉｏＣＥＰＴＡ Ｃｏｒｐｏｒａｔｉｏｎ Composition suitable for topical treatment of fungal infections of the skin and nails
NL2009407C2 (en) 2012-09-03 2014-03-04 Dutch Renewable Energy B V Antimicrobial composition.

Also Published As

Publication number Publication date
WO2016153331A1 (en) 2016-09-29
KR20170104575A (en) 2017-09-15
MX2015003641A (en) 2016-04-08
EA201700339A1 (en) 2018-02-28
CR20170320A (en) 2017-08-14
HK1249426A1 (en) 2018-11-02
US20200138755A1 (en) 2020-05-07
TN2017000257A1 (en) 2018-10-19
CA2972889C (en) 2019-04-23
GT201700149A (en) 2018-10-25
KR102057555B1 (en) 2019-12-19
AU2015387986B2 (en) 2018-12-20
EA036702B1 (en) 2020-12-09
CA2972889A1 (en) 2016-09-29
EP3219315A4 (en) 2017-12-06
EP3219315B1 (en) 2020-09-02
BR112017017189A2 (en) 2018-04-03
PH12017501157A1 (en) 2017-11-27
MX357998B (en) 2018-07-11
ECSP17056559A (en) 2017-10-31
CL2017001262A1 (en) 2017-09-29
IL253480B (en) 2020-05-31
US20180000764A1 (en) 2018-01-04
CN108024981A (en) 2018-05-11
US10688068B2 (en) 2020-06-23
SG11201705163XA (en) 2017-07-28
JP2018505191A (en) 2018-02-22
PE20180228A1 (en) 2018-01-31
DOP2017000161A (en) 2017-08-31
AU2015387986A1 (en) 2017-07-13
IL253480A0 (en) 2017-09-28
JP6771191B2 (en) 2020-10-21
NZ733186A (en) 2018-09-28
ES2850998T3 (en) 2021-09-02
CO2017007046A2 (en) 2018-01-05
EP3219315A1 (en) 2017-09-20
CN108024981B (en) 2021-07-20
MY173111A (en) 2019-12-27

Similar Documents

Publication Publication Date Title
PH12017501157A1 (en) Mixture of carboxylic acids for treating patients with kidney failure
PH12013502027A1 (en) Nutritional compositions having alpha-hica and alpha-ketoglutarate
EA200701218A1 (en) COMPOSITION FOR THE TREATMENT OF RETINOL-ASSOCIATED DISEASES
DK1853248T3 (en) Use of salts, addition compounds and complex compounds of quanidinoacetic acid
MY197091A (en) Compositions for treating acid-base disorders
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
SE1651735A1 (en) Substances for treatment of fatty liver-related conditions
GEP20186917B (en) Pharmaceutical preparation including pyridylamino acetic acid compound
JOP20200133A1 (en) Process for preparing (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid and its crystalline form for use as pharmaceutically active compound
MX2021014773A (en) Crystalline salt forms of a kinase inhibitor.
JOP20220042A1 (en) Methods for treating hyperphenylalaninemia
MX2009013937A (en) New use of known pharmacologically active chemical compounds.
JP2019037249A (en) Method for suppressing scorch of flowable nutritional composition containing l-arginine
MX2017004010A (en) A mixture of oxalacetate, alpha-ketoglutarate, tartaric acid and salts of calcium and sodium lactate, for treating patients with chronic renal insufficiency.
JP6234413B2 (en) Calcium-enriched soy sauce seasoning
WO2018004294A3 (en) Pharmaceutical composition comprising mutant human growth hormone protein or transferrin fusion protein thereof as effective ingredient
EA028055B8 (en) Amino acid composition for treating intrauterine foetal growth restriction (iugr) or for parenteral nutrition of extremely pre-term infants in weeks 24 to 34 of pregnancy
MX2020007462A (en) Methods of treating chronic inflammatory diseases.
MX2015006666A (en) Pharmaceutical composition for improving the general condition of chronic patients with states of energy and protein loss.
MX2022004944A (en) Compositions and methods for minimizing protein loss at low protein concentrations.